Other
Depreciation
Vertex Pharmaceuticals Depreciation remained flat by 0.0% to $38.95M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 2.9%, from $40.10M to $38.95M. Over 2 years (FY 2023 to FY 2025), Depreciation shows relatively stable performance with a -3.6% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
How to read this metric
High depreciation relative to revenue may indicate a capital-intensive business model or significant recent investment in infrastructure.
Detailed definition
The systematic allocation of the cost of tangible assets over their useful lives. This non-cash expense reflects the wea...
Peer comparison
Standard accounting metric across all capital-intensive industries.
Metric ID:
other_depreciationHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $167.80M | $160.40M | $155.80M |
| YoY Change | — | -4.4% | -2.9% |
Range$155.80M – $167.80M
CAGR-3.6%
Avg YoY Growth-3.6%
Median YoY Growth-3.6%
Current Streak2+ years decline
Depreciation at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's depreciation?
- Vertex Pharmaceuticals (VRTX) reported depreciation of $38.95M in Q4 2025.
- How has Vertex Pharmaceuticals's depreciation changed year-over-year?
- Vertex Pharmaceuticals's depreciation decreased by 2.9% year-over-year, from $40.10M to $38.95M.
- What is the long-term trend for Vertex Pharmaceuticals's depreciation?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's depreciation has grown at a -3.6% compound annual growth rate (CAGR), from $167.80M to $155.80M.
- What does depreciation mean?
- The annual expense representing the aging and usage of physical assets.